ALNY Alnylam Pharmaceuticals, Inc. - Common Stock
$240,12
Kurs · Aug 19, 2026
Fundamentaldaten per Jul 30, 2026
52W-Spanne
$198–$496
14% of range
Analystenbewertung
BUY
37 analysts
Kursziel
$376
+56% upside
P/E (TTM)
103.9
ROE
60.4%
Nettogewinnmarge
8.5%
Über Alnylam Pharmaceuticals, Inc. - Common Stock Unternehmensübersicht von Wikipedia
Alnylam Pharmaceuticals ist ein US-amerikanisches medizinisches Forschungsunternehmen, das 2002 gegründet wurde. Alnylam hat seinen Hauptsitz in Cambridge, MA. Die europäische Zentrale befindet sich in Maidenhead, UK. und die deutsche Niederlassung in München. Das Unternehmen macht sich die Entdeckung der RNA-Interferenz der beiden Nobelpreisträger Andrew Z. Fire und Craig C. Mello zunutze. Mitgründer des Unternehmens sind der Nobelpreisträger Phillip Allen Sharp und der Deutsche Thomas Tuschl, der einen wesentlichen Anteil an der Entdeckung der RNA-Interferenz in Säugetierzellen hatte. Alnylam ist eine Ausgründung aus dem damaligen Max-Planck-Institut für biophysikalische Chemie.
Mehr lesen
Alnylam Pharmaceuticals (Nasdaq: ALNY) ist ein US-amerikanisches medizinisches Forschungsunternehmen, das 2002 gegründet wurde. Alnylam hat seinen Hauptsitz in Cambridge, MA. Die europäische Zentrale befindet sich in Maidenhead, UK. und die deutsche Niederlassung in München. Das Unternehmen macht sich die Entdeckung der RNA-Interferenz der beiden Nobelpreisträger Andrew Z. Fire und Craig C. Mello zunutze. Mitgründer des Unternehmens sind der Nobelpreisträger Phillip Allen Sharp und der Deutsche Thomas Tuschl, der einen wesentlichen Anteil an der Entdeckung der RNA-Interferenz in Säugetierzellen hatte. Alnylam ist eine Ausgründung aus dem damaligen Max-Planck-Institut für biophysikalische Chemie.
Tätigkeitsgebiet
Alnylam überführt seit einigen Jahren die RNA-Interferenz (RNAi oder auch RNA-Silencing) bzw. die Gen-Stilllegung in eine neue Klasse von Medikamenten, die RNAi-Therapeutika. In den Biowissenschaften hat sich RNA-Interferenz als eine erfolgreiche Möglichkeit zur Stilllegung von Genen („Gen-Knockdown“) etabliert. Für die Entdeckung des Mechanismus der RNA-Interferenz (1998) erhielten die beiden US-Wissenschaftler Andrew Z. Fire und Craig C. Mello 2006 den Nobelpreis für Physiologie oder Medizin.
Noch verdient Alnylam kein Geld, sondern schreibt Verluste. Die Verluste ("GAAP operating loss") von Alnylam betrugen Ende 2020 circa 650 Mio. US-Dollar. Alnylam rechnet aber damit, 2025 finanziell Nettogewinne zu erzielen.
Medikamente / Pipeline
Alnylams Forschung fokussiert auf vier strategische therapeutische Gebiete:
Genetische Erbkrankheiten,
Kardiovaskuläre, metabolische Erkrankungen
hepatische Infektionskrankheiten
und Erkrankungen des zentralen Nervensystems und des Auges. Hier kooperiert Alnylam mit Regeneron.
Bei den meisten von Alnylams erforschten Erkrankungen handelt es sich um so genannte "Seltene Krankheiten" (auch Orphan Diseases genannt). Folgende fünf Medikamente sind in den USA und in der EU (und teilweise auch in noch weiteren Ländern) zugelassen:
Patisiran (Onpattro): Hereditäre ATTR-Amyloidose; weitere Indikationen werden untersucht.
Givosiran (Givlaari): Akute Intermittierende Porphyrie
Lumasiran (Oxlumo): Primäre Hyperoxalurie Typ 1 (PH1); weitere Indikationen werden untersucht.
Inclisiran (Leqvio): Hypercholesterinämie
Vutrisiran (Amvuttra): hereditäre Transthyretin-Amyloidose (ATTRv-Amyloidose) mit Polyneuropathie
Vutrisiran wurde in der HELIOS-B Studie für Wildtyp-Transthyretin(ATTR)-Amyloidose und hereditäre ATTR-Amyloidose mit Kardiomyopathie untersucht. Die Studie wurde im August 2024 publiziert und am ESC-Kongress vorgestellt.
Die Einreichung des Zulassungsantrags als Indiktionserweiterung erfolgte Anfang Oktober bei der FDA und Mitte Oktober 2024 bei der EMA.
Weitere Medikamente befinden sich noch in der klinischen Forschung, z. B.:
Fitusiran (Phase II): Hämophilie
Cemdisiran (Phase II): atypisches Hämolytisch-urämisches Syndrom
Zilebesiran ALN-AGT (Phase II): Bluthochdruck
Kooperationen
Alnylam kooperiert sowohl mit Genzyme, einer Tochter von Sanofi, Merck, also Merck Sharp & Dohme (kurz MSD), Novartis, The Medicines Company und mit zahlreichen weiteren Unternehmen.
2003 verschmolz Alnylam durch Aktientausch mit der 2000 gegründeten Ribopharma AG.
2017 wurde die strategische Allianz mit Vir bekannt gegeben zur Entwicklung von Therapien gegen Virusinfektionen, seit 2020 auch ein Projekt für eine COVID-19 Therapie auf RNAi-Basis.
Quelle: Wikipedia, CC BY-SA 4.0 · Auf Wikipedia ansehen ↗
ALNY Aktien-Snapshot Kurs, Marktkapitalisierung, P/E, EPS, ROE, Schulden/Eigenkapital, 52-Wochen-Spanne
Kurs
$240.12
Marktkapitalisierung
$32.04B
P/E (TTM)
103.9
EPS (TTM)
$2.33
Umsatz (TTM)
$3.71B
Dividendenrendite
—
ROE
60.4%
Verschuldungsgrad
—
52W-Spanne
$198 – $496
ALNY Aktienkurs-Chart Täglich OHLCV mit technischen Indikatoren — Schwenken, Zoom und Ansicht anpassen
Configure
10-Jahres-Performance Umsatz-, Nettoergebnis-, Margen- und EPS-Trends
Umsatz & Nettoergebnis
$3.71B
2016-12-31
→
2025-12-31
EPS
$2.33
2019-12-31
→
2025-12-31
Freier Cashflow
$465M
2016-12-31
→
2025-12-31
Margen
8.5%
Bewertung P/E-, P/S-, P/B-, EV/EBITDA-Verhältnisse — ist die Aktie teuer oder günstig?
Kennzahl
5-Jahres-Trend
ALNY
Peer-Median
P/E (TTM)
103.9
17.7
P/S (TTM) (K/V (TTM))
8.6
6.8
P/B (K/B)
40.6
6.4
Price / FCF (Kurs / FCF)
68.9
—
Rentabilität Brutto-, Betriebs- und Nettomargen; ROE, ROA, ROIC
Kennzahl
5-Jahres-Trend
ALNY
Peer-Median
Operating Margin (Betriebsgewinnmarge)
13.5%
—
Net Profit Margin (Nettogewinnmarge)
8.5%
20.3%
ROA
6.8%
11.4%
ROE
60.4%
16.8%
ROIC
61.7%
—
Finanzielle Gesundheit Verschuldung, Liquidität, Solvenz — Bilanzstärke
Kennzahl
5-Jahres-Trend
ALNY
Peer-Median
Current Ratio (Liquiditätsgrad)
2.8
3.4
Quick Ratio
1.7
—
Wachstum Umsatz-, EPS- und Nettoergebniswachstum: YoY, 3-Jahres-CAGR, 5-Jahres-CAGR
Kennzahl
5-Jahres-Trend
ALNY
Peer-Median
Revenue YoY (Umsatz YoY)
65.2%
—
Revenue CAGR 3Y (Umsatz CAGR 3J)
53.0%
—
Revenue CAGR 5Y (Umsatz CAGR 5J)
49.8%
—
Kapitaleffizienz Umsatz pro Vermögenswert, Lagerumschlag, Forderungsumschlag
Kennzahl
5-Jahres-Trend
ALNY
Peer-Median
ALNY Analysten-Konsens Bullische und bärische Analystenmeinungen, 12-Monats-Kursziel, Aufwärtspotenzial
KAUF
37 Analysten
- Starker Kauf 8 21,6%
- Kauf 21 56,8%
- Halten 8 21,6%
- Verkauf 0 0,0%
- Starker Verkauf 0 0,0%
12-Monats-Kursziel
24 Analysten · 2026-08-14
Median
$353.50
Jetzt
$240.12
Tief
$230.00
Hoch
$536.00
Median-Ziel
$353.50
+47,2%
Mittelwert-Ziel
$375.76
+56,5%
Ergebnisverlauf EPS Ist vs. Schätzung, Überraschung %, Beat-Rate, nächstes Ergebnisdatum
Durchschn. Überraschung
0.33%
| Zeitraum | EPS Actual | EPS est. | Überraschung |
|---|---|---|---|
| 30. Juni 2026 | $1.21 | $1.59 | -0.38% |
| 31. März 2026 | $1.51 | $0.98 | 0.53% |
| 31. Dezember 2025 | $0.82 | $1.15 | -0.33% |
| 30. September 2025 | $2.11 | $0.76 | 1.3% |
| 30. Juni 2025 | $-0.51 | $-0.73 | 0.22% |
| 31. März 2025 | $-0.44 | $-1.03 | 0.59% |
Peer-Vergleich (GICS-Subbranche) Wichtige Kennzahlen im Vergleich zu Branchenkollegen
| Ticker | Marktkapitalisierung | P/E | Umsatz Vj. | Nettomarge | ROE | Bruttogewinnmarge |
|---|---|---|---|---|---|---|
| ALNY | $52.64B | 170.7 | 65.2% | 8.5% | 60.4% | — |
| REGN | $106.21B | 18.6 | 0.99% | 31.4% | 14.7% | — |
| RVMD | — | — | — | — | — | — |
| NTRA | $32.00B | -150.7 | 35.9% | -9.0% | -14.1% | — |
| BIIB | $25.84B | 20.0 | 2.2% | 13.1% | 7.2% | — |
| INSM | $37.29B | -27.1 | 66.7% | -210.5% | -128.4% | — |
| INCY | $19.60B | 15.4 | 21.2% | 25.0% | 27.6% | — |
| MRNA | $11.62B | -4.1 | -39.9% | -145.2% | -31.3% | — |
| UTHR | $21.27B | 17.5 | 10.6% | 41.9% | 18.7% | 87.9% |
| BBIO | $14.90B | -20.2 | 126.3% | -146.0% | 41.2% | — |
Vollständige Fundamentaldaten Alle Kennzahlen nach Jahr — Gewinn- und Verlustrechnung, Bilanz, Cashflow
Gewinn- und Verlustrechnung 17
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $3.71B | $2.25B | $1.83B | $1.04B | $844M | $493M | $220M | $75M | $90M | $47M | · | · | |
| Cost of Revenue | $677M | $307M | $268M | $140M | $115M | $74M | $25M | $2M | $0 | · | · | · | |
| R&D Expense | $1.32B | $1.13B | $1.00B | $883M | $792M | $655M | $655M | $505M | $391M | $382M | $276M | $190M | |
| SG&A Expense | $1.21B | $976M | $796M | $771M | $621M | $588M | $479M | $382M | $199M | $89M | $61M | $45M | |
| Operating Expenses | $3.21B | $2.43B | $2.11B | $1.82B | $1.55B | $1.32B | $1.16B | $890M | $590M | $472M | $337M | $456M | |
| Operating Income | $502M | $-177M | $-282M | $-785M | $-709M | $-828M | $-939M | $-815M | $-500M | $-425M | $-296M | $-405M | |
| Interest Expense | · | · | $121M | $156M | $143M | $84M | $0 | $0 | · | · | · | · | |
| Interest Income | $111M | $122M | $96M | $25M | $2M | $12M | $33M | $29M | · | · | · | · | |
| Other Non-op | $5M | $-181M | $-126M | $-134M | $-2M | $57M | $21M | $25M | $-3M | $6M | $76.0K | $2M | |
| Pretax Income | $323M | $-377M | $-434M | $-1.13B | $-852M | $-856M | $-885M | $-761M | $-491M | $-410M | $-290M | $-401M | |
| Income Tax | $9M | $-99M | $7M | $4M | $680.0K | $3M | $863.0K | $823.0K | $0 | $0 | $0 | $-40M | |
| Net Income | $314M | $-278M | $-440M | $-1.13B | $-853M | $-858M | $-886M | $-761M | $-491M | $-410M | $-290M | $-360M | |
| EPS (Basic) | $2.39 | $-2.18 | $-3.52 | $-9.30 | $-7.20 | $-7.46 | $-8.11 | · | · | · | · | · | |
| EPS (Diluted) | $2.33 | $-2.18 | $-3.52 | $-9.30 | $-7.20 | $-7.46 | $-8.11 | · | · | · | · | · | |
| Shares (Basic) | 131,004,000 | 127,651,000 | 124,906,000 | 121,689,000 | 118,451,000 | 114,986,000 | 109,264,000 | · | · | · | · | · | |
| Shares (Diluted) | 134,684,000 | 127,651,000 | 124,906,000 | 121,689,000 | 118,451,000 | 114,986,000 | 109,264,000 | · | · | · | · | · | |
| EBITDA | $557M | $-120M | $-228M | $-741M | $-661M | $-794M | $-922M | $-808M | $-487M | $-409M | $-277M | $-393M |
Bilanz 23
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $1.66B | $966M | $813M | $866M | $820M | $497M | $547M | $420M | $645M | $194M | $181M | $75M | |
| Receivables | $778M | $405M | $328M | $238M | $199M | $102M | $43M | $19M | $34M | $23M | $8M | $40M | |
| Inventory | $83M | $79M | $89M | $129M | $86M | $75M | $56M | $24M | · | · | · | · | |
| Prepaid Expense | $282M | $117M | $126M | $133M | $88M | $63M | $80M | $74M | $40M | $22M | $17M | $10M | |
| Current Assets | $4.05B | $3.30B | $2.98B | $2.69B | $2.81B | $2.61B | $1.72B | $1.20B | $1.76B | $672M | $1.11B | $746M | |
| PP&E (Net) | $513M | $503M | $526M | $523M | $502M | $465M | $425M | $321M | $182M | $115M | $28M | $22M | |
| PP&E (Gross) | $836M | $773M | $749M | $697M | $642M | $569M | $501M | $400M | $249M | $176M | $79M | $68M | |
| Accum. Depreciation | $323M | $270M | $223M | $173M | $140M | $104M | $76M | $79M | $67M | $61M | $51M | $46M | |
| Other Non-current Assets | $59M | $65M | $62M | $66M | $60M | $45M | $18M | $9M | $4M | $2M | $1M | · | |
| Total Assets | $4.97B | $4.24B | $3.83B | $3.55B | $3.64B | $3.41B | $2.40B | $1.57B | $1.99B | $1.26B | $1.39B | $1.08B | |
| Accounts Payable | $116M | $88M | $56M | $98M | $73M | $52M | $50M | $60M | $28M | $54M | $17M | $15M | |
| Accrued Liabilities | $1.08B | $794M | $713M | $545M | $395M | $356M | $197M | $113M | $72M | $42M | $29M | $24M | |
| Current Liabilities | $1.47B | $1.19B | $968M | $768M | $696M | $585M | $353M | $179M | $144M | $132M | $62M | $95M | |
| Capital Leases | $225M | $230M | $243M | $261M | $281M | $293M | $276M | · | · | · | · | · | |
| Other Non-current Liabilities | $8M | $5M | $308M | $213M | $99M | $38M | $9M | $5M | $4M | $3M | $1M | · | |
| Total Liabilities | $4.18B | $4.17B | $4.05B | $3.70B | $3.06B | $2.39B | $956M | $273M | $228M | $343M | $122M | $143M | |
| Long-term Debt | · | · | · | · | $676M | $191M | · | · | · | · | · | · | |
| Common Stock | $1M | $1M | $1M | $1M | $1M | $1M | $1M | $1M | $997.0K | $859.0K | $851.0K | $772.0K | |
| Retained Earnings | $-6.70B | $-7.29B | $-7.01B | $-6.57B | $-5.44B | $-4.59B | $-3.73B | $-2.84B | $-2.15B | $-1.66B | $-1.25B | $-957M | |
| AOCI | $-20M | $-35M | $-23M | $-45M | $-33M | $-44M | $-37M | $-33M | $-34M | $-33M | $4M | $49M | |
| Stockholders' Equity | $789M | $67M | $-221M | $-158M | $588M | $1.02B | $1.44B | $1.30B | $1.77B | $920M | $1.26B | $936M | |
| Liabilities + Equity | $4.97B | $4.24B | $3.83B | $3.55B | $3.64B | $3.41B | $2.40B | $1.57B | $1.99B | $1.26B | $1.39B | $1.08B | |
| Shares Outstanding | 132,376,000 | 129,294,000 | 125,794,000 | 123,925,000 | 120,182,000 | 116,427,000 | 112,188,000 | 101,177,000 | 99,667,000 | 85,941,000 | 85,090,968 | 77,202,753 |
Cashflow 14
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $56M | $57M | $54M | $44M | $48M | $35M | $17M | $15M | $12M | $15M | $19M | $12M | |
| Stock-based Comp | $348M | $272M | $222M | $231M | $166M | $140M | $175M | $158M | $93M | $76M | $46M | $33M | |
| Deferred Tax | $-2M | $-107M | $-713.0K | $-1M | $-3M | $-3M | $-2M | $-788.0K | $0 | · | · | · | |
| Other Non-cash | $-191M | $48M | $269M | $316M | $614.0K | $72M | $418M | $35M | $2M | $12M | $36M | $150M | |
| Operating Cash Flow | $524M | $-8M | $104M | $-541M | $-642M | $-615M | $-278M | $-563M | $-383M | $-308M | $-189M | $-166M | |
| CapEx | $59M | $34M | $62M | $72M | $76M | $70M | $140M | $127M | $104M | $65M | $13M | $9M | |
| Investing Cash Flow | $436M | $-117M | $-336M | $169M | $-273M | $-436M | $-418M | $273M | $-290M | $143M | · | · | |
| Stock Issued | · | · | · | · | $0 | $0 | $382M | $0 | $1.14B | · | $496M | · | |
| Net Stock Activity | · | · | · | · | $0 | $0 | $382M | · | $1.14B | · | $496M | · | |
| Financing Cash Flow | $-305M | $294M | $172M | $426M | $1.25B | $995M | $823M | $65M | $1.12B | $178M | · | · | |
| Net Change in Cash | $690M | $154M | $-54M | $46M | $323M | $-51M | $127M | $-224M | $452M | $13M | $106M | $22M | |
| Taxes Paid | $15M | $14M | $6M | $3M | · | · | · | · | · | $111.0K | $66.0K | $-517.0K | |
| Free Cash Flow | $465M | $-43M | $42M | $-613M | $-718M | $-685M | $-419M | $-690M | $-487M | $-372M | $-202M | $-175M | |
| Levered FCF | · | · | $-81M | $-770M | $-861M | $-770M | · | · | · | · | · | · |
Rentabilität 7
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | 13.5% | -7.9% | -15.4% | -75.7% | -83.9% | -168.1% | -427.5% | -1087.6% | · | · | · | · | |
| Net Margin | 8.5% | -12.4% | -24.1% | -109.0% | -101.0% | -174.2% | -403.2% | -1016.6% | · | · | · | · | |
| Pretax Margin | 8.7% | -16.8% | -23.7% | -108.6% | -100.9% | -173.6% | -402.9% | -1015.5% | · | · | · | · | |
| EBITDA Margin | 15.0% | -5.3% | -12.5% | -71.4% | -78.3% | -161.0% | -419.7% | -1079.0% | · | · | · | · | |
| ROA | 6.8% | -6.9% | -11.9% | -31.5% | -24.2% | -29.6% | -44.6% | -42.7% | -30.1% | -31.0% | -23.5% | -48.0% | |
| ROE | 60.4% | -559.4% | 227.8% | 1001.6% | -126.9% | -76.9% | -58.2% | -54.8% | -36.5% | -37.5% | -26.4% | -59.7% | |
| ROIC | 61.7% | -194.3% | 129.9% | 498.0% | -120.6% | -81.8% | -65.4% | -62.6% | · | · | -23.4% | -38.9% |
Liquidität & Solvenz 3
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.8 | 2.8 | 3.1 | 3.5 | 4.0 | 4.5 | 4.9 | 6.7 | 12.2 | 5.1 | 17.8 | 7.8 | |
| Quick Ratio | 1.7 | 1.2 | 1.2 | 1.4 | 1.5 | 1.0 | 1.7 | 2.4 | 4.7 | 1.6 | 3.0 | 1.2 | |
| Interest Coverage | · | · | -2.3 | -5.0 | -5.0 | -9.8 | · | · | · | · | · | · |
Effizienz 3
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.8 | 0.6 | 0.5 | 0.3 | 0.2 | 0.2 | 0.1 | 0.0 | · | · | · | · | |
| Inventory Turnover | 8.4 | 3.7 | 2.5 | 1.3 | 1.4 | 1.2 | 0.6 | 0.1 | · | · | · | · | |
| Receivables Turnover | 6.3 | 6.1 | 6.5 | 4.8 | 5.6 | 6.8 | 7.1 | 2.8 | · | · | · | · |
Wachstumsraten 3
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 65.2% | 23.0% | 76.2% | 22.9% | 71.3% | · | · | · | · | · | · | · | |
| Revenue CAGR 3Y | 53.0% | 38.6% | 54.8% | · | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 49.8% | · | · | · | · | · | · | · | · | · | · | · |
Bewertung (TTM) 10
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $3.71B | $2.25B | $1.83B | $1.04B | $844M | $493M | $220M | $75M | $90M | $47M | $100M | $100M | |
| Net Income TTM | $314M | $-278M | $-440M | $-1.13B | $-853M | $-858M | $-886M | $-761M | $-491M | $-410M | $-290M | $-360M | |
| Market Cap | $52.64B | $30.42B | $24.08B | $29.45B | $20.38B | $15.13B | $12.92B | $7.38B | $12.66B | $3.22B | $8.01B | $7.49B | |
| P/E | 170.7 | -107.9 | -54.4 | -25.6 | -23.6 | -17.4 | -14.2 | · | · | · | · | · | |
| P/S | 14.2 | 13.5 | 13.2 | 28.4 | 24.1 | 30.7 | 58.8 | 98.5 | 140.8 | 68.2 | 80.3 | 75.1 | |
| P/B | 66.7 | 453.5 | -109.1 | -186.1 | 34.6 | 14.9 | 9.0 | 5.7 | 7.2 | 3.5 | 6.3 | 8.0 | |
| P / Tangible Book | 66.7 | 453.5 | · | · | 34.6 | 14.9 | · | · | · | · | · | · | |
| P / Cash Flow | 100.4 | -3660.3 | 231.2 | -54.4 | -31.8 | -24.6 | -46.4 | -13.1 | -33.1 | -10.5 | -42.4 | -45.2 | |
| P / FCF | 113.1 | -714.4 | 574.0 | -48.0 | -28.4 | -22.1 | -30.9 | -10.7 | -26.0 | -8.6 | -39.6 | -42.9 | |
| Earnings Yield | 0.59% | -0.93% | -1.8% | -3.9% | -4.2% | -5.7% | -7.0% | · | · | · | · | · |
Gewinn- und Verlustrechnung 17
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.29B | $1.17B | $1.10B | $1.25B | $774M | $594M | $593M | $501M | $660M | $494M | $440M | $751M | $319M | $319M | $335M | $264M | |
| Cost of Revenue | $298M | $208M | $268M | $197M | $142M | $70M | $103M | $82M | $67M | $55M | $72M | $79M | $75M | $41M | $46M | $37M | |
| R&D Expense | $413M | $365M | $372M | $359M | $324M | $265M | $300M | $271M | $294M | $261M | $272M | $253M | $249M | $231M | $262M | $245M | |
| SG&A Expense | $348M | $323M | $325M | $322M | $323M | $240M | $295M | $221M | $248M | $211M | $198M | $199M | $215M | $184M | $210M | $236M | |
| Operating Expenses | $1.06B | $899M | $965M | $881M | $790M | $576M | $698M | $578M | $611M | $538M | $556M | $537M | $549M | $469M | $524M | $522M | |
| Operating Income | $231M | $269M | $132M | $368M | $-16M | $18M | $-105M | $-77M | $49M | $-43M | $-116M | $214M | $-230M | $-150M | $-189M | $-258M | |
| Interest Expense | · | · | · | · | · | · | · | · | · | $35M | · | $31M | $30M | $29M | · | $41M | |
| Interest Income | $28M | $27M | $27M | $29M | $27M | $29M | $31M | $32M | $29M | $30M | $30M | $25M | $21M | $19M | $14M | $8M | |
| Other Non-op | $273.0K | $-4M | $135M | $-74M | $9M | $9M | $-81M | $-30M | $-56M | $-15M | $-20M | $-58M | $-35M | $-12M | $-3M | $-38M | |
| Pretax Income | $178M | $222M | $161M | $239M | $-41M | $-2M | $-194M | $-109M | $-11M | $-64M | $-138M | $151M | $-274M | $-172M | $-207M | $-406M | |
| Income Tax | $13M | $16M | $-25M | $-12M | $31M | $16M | $-110M | $3M | $6M | $2M | $183.0K | $3M | $2M | $2M | $472.0K | $-23.0K | |
| Net Income | $164M | $206M | $186M | $251M | $-72M | $-18M | $-84M | $-112M | $-17M | $-66M | $-138M | $148M | $-276M | $-174M | $-207M | $-406M | |
| EPS (Basic) | $1.23 | $1.55 | $1.43 | $1.91 | $-0.55 | $-0.14 | $-0.66 | $-0.87 | $-0.13 | $-0.52 | $-1.09 | $1.18 | $-2.21 | $-1.40 | $-1.69 | $-3.32 | |
| EPS (Diluted) | $1.21 | $1.51 | $1.44 | $1.84 | $-0.55 | $-0.14 | $-0.66 | $-0.87 | $-0.13 | $-0.52 | $-1.06 | $1.15 | $-2.21 | $-1.40 | $-1.69 | $-3.32 | |
| Shares (Basic) | 133,606,000 | 132,893,000 | -260,747,000 | 131,447,000 | 130,628,000 | 129,676,000 | -253,810,000 | 128,590,000 | 126,733,000 | 126,138,000 | -249,084,000 | 125,220,000 | 124,659,000 | 124,111,000 | -241,766,000 | 122,166,000 | |
| Shares (Diluted) | 138,281,000 | 138,226,000 | -262,968,000 | 137,348,000 | 130,628,000 | 129,676,000 | -253,810,000 | 128,590,000 | 126,733,000 | 126,138,000 | -255,201,000 | 131,337,000 | 124,659,000 | 124,111,000 | -241,766,000 | 122,166,000 | |
| EBITDA | $231M | $282M | · | $368M | $-16M | $32M | · | $-77M | $49M | $-30M | · | $214M | $-230M | $-136M | · | $-258M |
Bilanz 22
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $1.71B | $1.71B | $1.66B | $1.49B | $1.11B | $1.02B | $966M | $1.10B | $968M | $682M | $813M | $1.03B | $658M | $672M | $866M | $1.07B | |
| Receivables | $913M | $884M | $778M | $965M | $567M | $418M | $405M | $354M | $309M | $321M | · | $325M | $221M | $219M | · | $185M | |
| Inventory | $97M | $84M | $83M | $75M | $72M | $66M | $79M | $76M | $84M | $94M | · | $96M | $100M | $132M | · | $115M | |
| Prepaid Expense | $302M | $242M | $282M | $188M | $147M | $152M | $117M | $145M | $155M | $202M | · | $158M | $145M | $119M | · | $126M | |
| Current Assets | $4.62B | $4.22B | $4.05B | $3.95B | $3.64B | $3.27B | $3.30B | $3.36B | $3.17B | $2.99B | · | $2.99B | $2.52B | $2.54B | · | $2.69B | |
| PP&E (Net) | $554M | $518M | $513M | $502M | $500M | $499M | $503M | $507M | $517M | $523M | · | $526M | $527M | $523M | · | $515M | |
| PP&E (Gross) | · | · | $836M | · | · | · | $773M | · | · | · | · | · | · | · | · | · | |
| Accum. Depreciation | · | · | $323M | · | · | · | $270M | · | · | · | · | · | · | · | · | · | |
| Other Non-current Assets | $65M | $64M | $59M | $56M | $57M | $74M | $65M | $78M | $72M | $67M | · | $75M | $93M | $63M | · | $61M | |
| Total Assets | $5.56B | $5.13B | $4.97B | $4.85B | $4.57B | $4.21B | $4.24B | $4.21B | $4.01B | $3.82B | · | $3.84B | $3.40B | $3.39B | · | $3.54B | |
| Accounts Payable | $108M | $127M | $116M | $118M | $102M | $97M | $88M | $71M | $74M | $78M | · | $74M | $60M | $62M | · | $41M | |
| Accrued Liabilities | $1.10B | $946M | $1.08B | $1.15B | $919M | $704M | $794M | $946M | $809M | $699M | · | $713M | $599M | $509M | · | $511M | |
| Current Liabilities | $1.51B | $1.35B | $1.47B | $1.56B | $1.30B | $1.08B | $1.19B | $1.22B | $1.06B | $942M | · | $950M | $789M | $673M | · | $773M | |
| Capital Leases | $210M | $218M | $225M | $223M | $224M | $230M | $230M | $236M | $239M | $238M | · | $248M | $253M | $259M | · | $266M | |
| Other Non-current Liabilities | $9M | $8M | $8M | $10M | $11M | $6M | $5M | $357M | $350M | $320M | · | $281M | $257M | $224M | · | $183M | |
| Total Liabilities | $4.20B | $4.05B | $4.18B | $4.62B | $4.32B | $4.10B | $4.17B | $4.17B | $4.01B | $4.04B | · | $4.00B | $3.81B | $3.65B | · | $3.60B | |
| Common Stock | $1M | $1M | $1M | $1M | $1M | $1M | $1M | $1M | $1M | $1M | · | $1M | $1M | $1M | · | $1M | |
| Retained Earnings | $-6.33B | $-6.50B | $-6.70B | $-7.16B | $-7.41B | $-7.35B | $-7.29B | $-7.20B | $-7.09B | $-7.08B | · | $-6.87B | $-7.02B | $-6.74B | · | $-6.36B | |
| AOCI | $-32M | $-25M | $-20M | $-22M | $-30M | $-38M | $-35M | $-25M | $-35M | $-27M | · | $-32M | $-37M | $-39M | · | $-44M | |
| Stockholders' Equity | $1.35B | $1.08B | $789M | $234M | $251M | $115M | $67M | $32M | $-3M | $-219M | $-221M | $-166M | $-408M | $-259M | $-158M | $-68M | |
| Liabilities + Equity | $5.56B | $5.13B | $4.97B | $4.85B | $4.57B | $4.21B | $4.24B | $4.21B | $4.01B | $3.82B | · | $3.84B | $3.40B | $3.39B | · | $3.54B | |
| Shares Outstanding | 133,734,000 | 133,444,000 | 132,376,000 | 131,791,000 | 130,977,000 | 130,311,000 | 129,294,000 | 128,841,000 | 128,021,000 | 126,463,000 | 125,794,000 | 125,454,000 | 124,901,000 | 124,241,000 | 123,925,000 | 122,991,000 |
Cashflow 12
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $14M | $14M | $14M | $14M | $14M | $14M | $14M | $14M | $15M | $14M | $13M | $13M | $13M | $14M | $14M | $11M | |
| Stock-based Comp | $87M | $70M | $72M | $108M | $112M | $57M | $92M | $46M | $89M | $45M | $42M | $64M | $76M | $40M | $43M | $128M | |
| Deferred Tax | $3M | $9M | $-27M | $6M | $10M | $10M | $-107M | $-163.0K | $340.0K | $454.0K | · | · | · | · | · | · | |
| Other Non-cash | · | $-229M | · | · | · | $-142M | · | · | · | $-74M | · | · | · | $-46M | · | · | |
| Operating Cash Flow | $327M | $71M | $164M | $325M | $154M | $-120M | $-95M | $44M | $124M | $-82M | $-30M | $359M | $-59M | $-166M | $-132M | $-115M | |
| CapEx | $35M | $22M | $23M | $12M | $14M | $9M | $9M | $4M | $8M | $13M | $15M | $17M | $16M | $14M | $22M | $17M | |
| Investing Cash Flow | $-363M | $-26M | $-37M | $501M | $-141M | $114M | $-53M | $-30M | $34M | $-68M | $-241M | $-11M | $-9M | $-76M | $-140M | $314M | |
| Financing Cash Flow | $36M | $16M | $45M | $-448M | $54M | $46M | $31M | $103M | $131M | $29M | $39M | $33M | $53M | $46M | $63M | $297M | |
| Net Change in Cash | $-3M | $54M | $166M | $377M | $94M | $54M | $-134M | $131M | $286M | $-130M | $-220M | $375M | $-14M | $-194M | $-207M | $498M | |
| Taxes Paid | $12M | $2M | $13M | $1M | $-2M | $3M | · | $5M | $2M | $2M | · | · | · | · | · | · | |
| Free Cash Flow | · | $49M | · | · | · | $-127M | · | · | · | $-94M | · | · | · | $-180M | · | · | |
| Levered FCF | · | · | · | · | · | · | · | · | · | $-131M | · | · | · | $-210M | · | · |
Rentabilität 7
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | 17.9% | 23.0% | · | 29.5% | -2.1% | 3.0% | · | -15.3% | 7.4% | -8.8% | · | 28.5% | -72.1% | -46.9% | · | -97.6% | |
| Net Margin | 12.7% | 17.6% | · | 20.1% | -8.6% | -9.7% | · | -22.3% | -2.6% | -13.3% | · | 19.7% | -86.6% | -54.5% | · | -153.6% | |
| Pretax Margin | 13.8% | 19.0% | · | 19.1% | -4.6% | -7.0% | · | -21.7% | -1.7% | -12.9% | · | 20.1% | -86.0% | -54.0% | · | -153.6% | |
| EBITDA Margin | 17.9% | 24.2% | · | 29.5% | -2.1% | 5.5% | · | -15.3% | 7.4% | -6.0% | · | 28.5% | -72.1% | -42.5% | · | -97.6% | |
| ROA | 3.2% | 4.4% | · | 5.5% | -1.6% | -1.4% | · | -2.8% | -0.46% | -1.8% | · | 4.0% | -8.2% | -5.1% | · | -11.6% | |
| ROE | 20.5% | 34.6% | · | 188.6% | -53.5% | 110.7% | · | 167.1% | 8.2% | 27.6% | · | -126.6% | 237.9% | -245.3% | · | -118.0% | |
| ROIC | 15.8% | 23.2% | · | 165.3% | -12.1% | 21.6% | · | -244.1% | -2397.3% | 20.5% | · | -126.4% | 56.7% | 58.4% | · | 381.5% |
Liquidität & Solvenz 3
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 3.1 | 3.1 | · | 2.5 | 2.8 | 3.0 | · | 2.7 | 3.0 | 3.2 | · | 3.1 | 3.2 | 3.8 | · | 3.5 | |
| Quick Ratio | 1.7 | 1.9 | · | 1.6 | 1.3 | 1.3 | · | 1.2 | 1.2 | 1.1 | · | 1.4 | 1.1 | 1.3 | · | 1.6 | |
| Interest Coverage | · | · | · | · | · | · | · | · | · | -1.2 | · | 6.9 | -7.7 | -5.2 | · | -6.3 |
Effizienz 3
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.3 | 0.2 | · | 0.3 | 0.2 | 0.1 | · | 0.1 | 0.2 | 0.1 | · | 0.2 | 0.1 | 0.1 | · | 0.1 | |
| Inventory Turnover | 3.5 | 2.8 | · | 2.6 | 1.8 | 0.9 | · | 1.0 | 0.7 | 0.5 | · | 0.8 | 0.8 | 0.4 | · | 0.3 | |
| Receivables Turnover | 1.7 | 1.8 | · | 1.9 | 1.8 | 1.6 | · | 1.5 | 2.5 | 1.8 | · | 2.9 | 1.8 | 1.7 | · | 1.6 |
Bewertung (TTM) 10
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $4.48B | $3.78B | · | $3.12B | $2.53B | $2.25B | · | $2.41B | $2.22B | $1.88B | · | $1.65B | $1.13B | $1.02B | · | $890M | |
| Net Income TTM | $549M | $373M | · | $55M | $-213M | $-213M | · | $-47M | $-211M | $-368M | · | $-708M | $-1.13B | $-1.10B | · | $-1.13B | |
| Market Cap | $40.26B | $44.15B | · | $60.10B | $42.71B | $35.19B | · | $35.44B | $31.11B | $18.90B | · | $22.22B | $23.72B | $24.89B | · | $24.62B | |
| P/E | 75.1 | 122.5 | · | 1425.0 | -197.6 | -162.7 | · | -743.3 | -142.1 | -50.2 | · | -30.6 | -20.6 | -22.2 | · | -21.5 | |
| P/S | 9.0 | 11.7 | · | 19.3 | 16.9 | 15.6 | · | 14.7 | 14.0 | 10.0 | · | 13.4 | 21.0 | 24.4 | · | 27.7 | |
| P/B | 29.7 | 41.1 | · | 256.9 | 170.4 | 304.8 | · | 1095.2 | -10143.2 | -86.2 | · | -134.0 | -58.1 | -96.0 | · | -364.0 | |
| P / Tangible Book | 29.7 | 41.1 | · | 256.9 | 170.4 | 304.8 | · | 1095.2 | · | · | · | · | · | · | · | · | |
| P / Cash Flow | · | 626.2 | · | · | · | -297.4 | · | · | · | -231.9 | · | · | · | -149.5 | · | · | |
| P / FCF | · | 907.2 | · | · | · | -276.4 | · | · | · | -200.0 | · | · | · | -138.0 | · | · | |
| Earnings Yield | 1.3% | 0.82% | · | 0.07% | -0.51% | -0.61% | · | -0.13% | -0.70% | -2.0% | · | -3.3% | -4.9% | -4.5% | · | -4.7% |
Finanzberichte Gewinn- und Verlustrechnung, Bilanz, Cashflow — jährlich, letzte 5 Jahre
Gewinn- und Verlustrechnung
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Umsatz | $3.71B | $2.25B | $1.83B | $1.04B | $844M |
| Betriebsgewinnmarge % | 13.5% | -7.9% | -15.4% | -75.7% | -83.9% |
| Nettoergebnis | $314M | $-278M | $-440M | $-1.13B | $-853M |
| Verwässerte EPS | $2.33 | $-2.18 | $-3.52 | $-9.30 | $-7.20 |
Bilanz
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Liquiditätsgrad | 2.8 | 2.8 | 3.1 | 3.5 | 4.0 |
| Quick Ratio | 1.7 | 1.2 | 1.2 | 1.4 | 1.5 |
Cashflow
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Freier Cashflow | $465M | $-43M | $42M | $-613M | $-718M |
Neueste Nachrichten Aktuelle Schlagzeilen über dieses Unternehmen
Meine Kennzahlen Ihre persönliche Watchlist — ausgewählte Zeilen aus den vollständigen Fundamentaldaten
📊
Wählen Sie die Kennzahlen, die für Sie wichtig sind — klicken Sie auf das ➕ neben jeder Zeile in den vollständigen Fundamentaldaten oben.
Ihre Auswahl wird gespeichert und begleitet Sie über alle Ticker hinweg.
Institutionelle Eigentümer (13F) 877 Einreicher · $27.1B gesamt · Stand 30. Juni 2026
Institutionen, die diese Aktie in ihrer vierteljährlichen SEC-Formular 13F melden. Nur Long-Positionen; ein einzelner Einreicher kann für separate Optionsscheine zweimal erscheinen. Große gegenläufige Put/Call-Positionen spiegeln typischerweise Market-Making oder abgesicherte Bestände wider, nicht die gerichtete Überzeugung.
Institutionelle Aktivität — Q2 2026 vs. Vorquartal
| Neue Positionen | Geschlossene Positionen | Erhöht | Abgenommen | Nettoveränderung der Aktien |
|---|---|---|---|---|
| 99 (-11 vs. Vorquartal) | 77 (-68 vs. Vorquartal) | 328 (+4 vs. Vorquartal) | 259 (+4 vs. Vorquartal) | +15.9M |
Verglichen mit Q1 2026. SEC-Formular 13F-Einreichungen sind innerhalb von 45 Tagen nach Quartalsende fällig, zuzüglich einer kurzen Pufferzeit für verspätete Einreicher — Quartale, die noch in diesem Fenster liegen, werden zugunsten des letzten vollständig berichteten Paares übersprungen.
| Institution | Wert | Aktien | % der verfolgten 13F | Typ |
|---|---|---|---|---|
| Capital World Investors | $3.354.715.611 | 11.144.846 | 12,36% | Aktien |
| FMR LLC | $3.108.157.652 | 10.325.076 | 11,45% | Aktien |
| Capital Research Global Investors | $2.935.115.324 | 9.750.699 | 10,81% | Aktien |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $1.968.251.542 | 6.538.390 | 7,25% | Aktien |
| VANGUARD CAPITAL MANAGEMENT LLC | $1.815.053.762 | 6.029.478 | 6,69% | Aktien |
| STATE STREET CORP | $1.070.369.060 | 3.555.689 | 3,94% | Aktien |
| GEODE CAPITAL MANAGEMENT, LLC | $686.853.582 | 2.288.725 | 2,53% | Aktien |
| NORGES BANK | $683.883.867 | 2.271.813 | 2,52% | Aktien |
| WELLINGTON MANAGEMENT GROUP LLP | $614.923.915 | 2.042.733 | 2,26% | Aktien |
| Dodge & Cox | $588.631.955 | 1.955.393 | 2,17% | Aktien |
| TWO SIGMA INVESTMENTS, LP | $564.713.315 | 1.875.937 | 2,08% | Aktien |
| AMERICAN CENTURY COMPANIES INC | $558.098.292 | 1.853.956 | 2,06% | Aktien |
| TWO SIGMA ADVISERS, LP | $450.362.484 | 1.132.560 | 1,66% | Aktien |
| Clearbridge Investments, LLC | $379.142.285 | 1.259.483 | 1,40% | Aktien |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE | $269.059.154 | 893.795 | 0,99% | Aktien |
| VANGUARD FIDUCIARY TRUST CO | $259.723.265 | 862.782 | 0,96% | Aktien |
| Deep Track Capital, LP | $248.349.750 | 825.000 | 0,91% | Aktien |
| Qube Research & Technologies Ltd | $240.437.176 | 798.715 | 0,89% | Aktien |
| LOS ANGELES CAPITAL MANAGEMENT LLC | $219.642.021 | 729.635 | 0,81% | Aktien |
| BANK OF AMERICA CORP /DE/ | $176.408.397 | 586.016 | 0,65% | Aktien |
| LOOMIS SAYLES & CO L P | $170.456.431 | 566.244 | 0,63% | Aktien |
| BAILLIE GIFFORD & CO | $165.849.468 | 550.940 | 0,61% | Aktien |
| ROYAL BANK OF CANADA | $154.998.000 | 514.893 | 0,57% | Aktien |
| Polar Capital Holdings Plc | $145.322.534 | 482.751 | 0,54% | Aktien |
| Paradigm Biocapital Advisors LP | $144.494.400 | 480.000 | 0,53% | Aktien |
| D. E. Shaw & Co., Inc. | $129.533.209 | 430.300 | 0,48% | Kaufoption |
| FIRST TRUST ADVISORS LP | $126.894.361 | 421.534 | 0,47% | Aktien |
| Swiss National Bank | $112.609.302 | 374.080 | 0,41% | Aktien |
| WELLS FARGO & COMPANY/MN | $111.381.100 | 370.000 | 0,41% | Kaufoption |
| BlackRock, Inc. | $102.807.465 | 341.519 | 0,38% | Aktien |
| CANADA PENSION PLAN INVESTMENT BOARD | $100.618.073 | 334.246 | 0,37% | Aktien |
| Sumitomo Mitsui Trust Group, Inc. | $97.948.840 | 325.379 | 0,36% | Aktien |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $97.804.647 | 324.900 | 0,36% | Kaufoption |
| Legal & General Group Plc | $97.467.493 | 323.780 | 0,36% | Aktien |
| MILLENNIUM MANAGEMENT LLC | $95.125.781 | 316.001 | 0,35% | Aktien |
| DIMENSIONAL FUND ADVISORS LP | $94.687.695 | 314.546 | 0,35% | Aktien |
| Candriam S.C.A. | $94.586.456 | 314.512 | 0,35% | Aktien |
| D. E. Shaw & Co., Inc. | $93.229.593 | 309.702 | 0,34% | Aktien |
| NOMURA ASSET MANAGEMENT INTERNATIONAL INC. | $90.367.000 | 300.193 | 0,33% | Aktien |
| DEUTSCHE BANK AG\ | $89.849.026 | 298.472 | 0,33% | Aktien |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $88.641.294 | 294.460 | 0,33% | Aktien |
| Pictet Asset Management Holding SA | $83.257.214 | 278.613 | 0,31% | Aktien |
| BNP PARIBAS FINANCIAL MARKETS | $81.586.054 | 271.023 | 0,30% | Aktien |
| GILDER GAGNON HOWE & CO LLC | $80.992.374 | 269.051 | 0,30% | Aktien |
| CONGRESS ASSET MANAGEMENT CO | $79.983.972 | 265.701 | 0,29% | Aktien |
| VANGUARD ASSET MANAGEMENT, Ltd | $77.578.441 | 257.710 | 0,29% | Aktien |
| California Public Employees Retirement System | $76.477.575 | 254.053 | 0,28% | Aktien |
| WESTFIELD CAPITAL MANAGEMENT CO LP | $75.974.872 | 252.383 | 0,28% | Aktien |
| Korea Investment CORP | $74.553.090 | 247.660 | 0,27% | Aktien |
| Woodline Partners LP | $74.138.270 | 246.282 | 0,27% | Aktien |
| Squarepoint Ops LLC | $70.440.719 | 233.999 | 0,26% | Aktien |
| TD Asset Management Inc | $70.349.507 | 233.696 | 0,26% | Aktien |
| CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | $65.136.061 | 196.863 | 0,24% | Aktien |
| ROYAL LONDON ASSET MANAGEMENT LTD | $64.296.696 | 213.589 | 0,24% | Aktien |
| National Pension Service | $59.692.744 | 198.295 | 0,22% | Aktien |
| PINEBRIDGE INVESTMENTS LLC | $58.914.280 | 195.709 | 0,22% | Aktien |
| Robeco Institutional Asset Management B.V. | $56.618.929 | 188.084 | 0,21% | Aktien |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $53.824.164 | 178.800 | 0,20% | Verkaufsoption |
| VICTORY CAPITAL MANAGEMENT INC | $52.030.628 | 172.842 | 0,19% | Aktien |
| Mitsubishi UFJ Asset Management Co., Ltd. | $50.772.924 | 168.664 | 0,19% | Aktien |
| RHUMBLINE ADVISERS | $49.844.185 | 165.579 | 0,18% | Aktien |
| Life Cycle Investment Partners Ltd | $49.797.587 | 165.424 | 0,18% | Aktien |
| ANTIPODES PARTNERS Ltd | $49.228.339 | 163.533 | 0,18% | Aktien |
| Universal- Beteiligungs- und Servicegesellschaft mbH | $47.228.883 | 157.223 | 0,17% | Aktien |
| CAPITAL FUND MANAGEMENT S.A. | $46.931.781 | 155.904 | 0,17% | Aktien |
| Assenagon Asset Management S.A. | $46.868.866 | 155.695 | 0,17% | Aktien |
| Vinva Investment Management Ltd | $45.487.381 | 154.972 | 0,17% | Aktien |
| JANUS HENDERSON GROUP PLC | $43.671.202 | 132.000 | 0,16% | Aktien |
| Hudson Bay Capital Management LP | $42.204.406 | 140.200 | 0,16% | Aktien |
| ENVESTNET ASSET MANAGEMENT INC | $41.059.106 | 136.395 | 0,15% | Aktien |
| ProShare Advisors LLC | $38.686.569 | 128.514 | 0,14% | Aktien |
| GOLDMAN SACHS GROUP INC | $37.029.700 | 123.010 | 0,14% | Aktien |
| LMR Partners LLP | $35.881.572 | 119.196 | 0,13% | Aktien |
| Man Group plc | $35.798.187 | 118.919 | 0,13% | Aktien |
| HSBC HOLDINGS PLC | $35.754.282 | 120.600 | 0,13% | Verkaufsoption |
| SCS Capital Management LLC | $34.783.715 | 115.549 | 0,13% | Aktien |
| AVIVA PLC | $34.477.568 | 114.532 | 0,13% | Aktien |
| Davern Capital Partners, LP | $34.041.978 | 113.085 | 0,13% | Aktien |
| STATE BOARD OF ADMINISTRATION OF FLORIDA RETIREMENT SYSTEM | $33.770.750 | 112.184 | 0,12% | Aktien |
| Longaeva Partners L.P. | $33.191.869 | 110.261 | 0,12% | Aktien |
| 683 Capital Management, LLC | $32.360.725 | 107.500 | 0,12% | Verkaufsoption |
| MARSHALL WACE, LLP | $32.215.929 | 107.019 | 0,12% | Aktien |
| HighTower Advisors, LLC | $31.621.666 | 105.045 | 0,12% | Aktien |
| Bridgewater Associates, LP | $29.977.772 | 99.584 | 0,11% | Aktien |
| Prosight Management, LP | $29.525.022 | 98.080 | 0,11% | Aktien |
| BNP PARIBAS ASSET MANAGEMENT Holding S.A. | $28.956.123 | 96.408 | 0,11% | Aktien |
| Andra AP-fonden | $28.685.436 | 86.697 | 0,11% | Aktien |
| SCHRODER INVESTMENT MANAGEMENT GROUP | $28.376.894 | 94.266 | 0,10% | Aktien |
| AMERIPRISE FINANCIAL INC | $28.191.159 | 93.649 | 0,10% | Aktien |
| BARCLAYS PLC | $27.979.234 | 92.945 | 0,10% | Aktien |
| TREMBLANT CAPITAL GROUP | $27.977.728 | 92.940 | 0,10% | Aktien |
| FIL Ltd | $27.652.616 | 91.860 | 0,10% | Aktien |
| Balyasny Asset Management L.P. | $26.945.195 | 89.510 | 0,10% | Aktien |
| Caisse de depot et placement du Quebec | $25.812.720 | 85.748 | 0,10% | Aktien |
| Mitsubishi UFJ Trust & Banking Corp | $24.911.136 | 82.753 | 0,09% | Aktien |
| RAYMOND JAMES FINANCIAL INC | $24.661.883 | 81.925 | 0,09% | Aktien |
| CITADEL ADVISORS LLC | $24.564.048 | 81.600 | 0,09% | Kaufoption |
| VANGUARD GROUP INC | $24.356.460 | 61.251 | 0,09% | Aktien |
| NEOS Investment Management LLC | $23.562.822 | 78.274 | 0,09% | Aktien |
| JONES FINANCIAL COMPANIES LLLP | $23.444.213 | 80.462 | 0,09% | Aktien |
Unternehmensinsider 41 Insider · 1 Führungskräfte · 13 Direktoren
| Insider | Rolle | Letzte Aktivität | Gehaltene Aktien | Käufe 12m | Verkäufe 12m | Netto 12m |
|---|---|---|---|---|---|---|
| Melissa Mclaughlin | Chief Human Resources Officer | 6. April 2026 S | 9.443 | 0 | 14 | $-1.274.343 |
| Colleen F Reitan | Direktor | 20. Mai 2026 A | 1.446 | 0 | 0 | $0 |
| Charles Elliott Sigal | Direktor | 20. Mai 2026 A | 1.446 | 0 | 0 | $0 |
| Stuart A Arbuckle | Direktor | 20. Mai 2026 A | 671 | 0 | 0 | $0 |
| Olivier Brandicourt | Direktor | 20. Mai 2026 A | 1.446 | 0 | 0 | $0 |
| Amy Schulman | Direktor | 20. Mai 2026 A | 24.049 | 0 | 0 | $0 |
| Dennis A Ausiello | Direktor | 20. Mai 2026 A | 1.582 | 0 | 0 | $0 |
| Margaret A Hamburg | Direktor | 20. Mai 2026 A | 1.582 | 0 | 0 | $0 |
| KELLOGG PETER N | Direktor | 20. Mai 2026 A | 1.446 | 0 | 0 | $0 |
| David E I Pyott | Direktor | 20. Mai 2026 A | 1.582 | 0 | 0 | $0 |
| Victor J Dzau | Direktor | 21. Juni 2012 A | — | 0 | 0 | $0 |
| Peter Barrett | Direktor | 1. Juni 2006 A | 5.293 | 0 | 0 | $0 |
| John E Berriman | Direktor | 8. Juni 2005 A | 2.475 | 0 | 0 | $0 |
| Christoph H Westphal | Direktor | 3. Juni 2004 C | 2.409.970 | 0 | 0 | $0 |
| Sanofi | 10%-Eigentümer | 31. Mai 2017 P | 10.554.134 | 0 | 0 | $0 |
| ALNYLAM PHARMACEUTICALS, INC. | 10%-Eigentümer | 23. Februar 2016 S | 4.896.716 | 0 | 0 | $0 |
| POLARIS VENTURE MANAGEMENT CO III LLC | 10%-Eigentümer | 3. Juni 2004 C | 2.409.970 | 0 | 0 | $0 |
| CHP II LP | 10%-Eigentümer | 27. Mai 2004 P | 232.500 | 0 | 0 | $0 |
| Akshay Vaishnaw | — | 10. August 2018 A | 395 | 0 | 0 | $0 |
| Barry E Greene | — | 10. August 2018 A | 9.030 | 0 | 0 | $0 |
| John Maraganore | — | 10. August 2018 A | 151.297 | 0 | 0 | $0 |
| SHARP PHILLIP A | — | 9. März 2018 M | 140.795 | 0 | 0 | $0 |
| Michael Mason | — | 4. Januar 2018 M | 0 | 0 | 0 | $0 |
| Laurie Keating | — | 29. Dezember 2017 M | 14.500 | 0 | 0 | $0 |
| Yvonne Greenstreet | — | 20. Dezember 2017 A | — | 0 | 0 | $0 |
| David-Alexandre C Gros | — | 20. Dezember 2016 A | — | 0 | 0 | $0 |
| SCHIMMEL PAUL | — | 19. November 2015 G | 306.996 | 0 | 0 | $0 |
| Marsha Fanucci | — | 1. Juni 2015 A | 10.000 | 0 | 0 | $0 |
| Steven M Paul | — | 1. Juni 2015 A | — | 0 | 0 | $0 |
| Michael W Bonney | — | 1. Juni 2015 A | — | 0 | 0 | $0 |
| John K Clarke | — | 1. Juni 2015 A | 2.091.868 | 0 | 0 | $0 |
| Kevin P Starr | — | 1. Juni 2015 A | — | 0 | 0 | $0 |
| Laurence Reid | — | 19. Mai 2014 M | 3.905 | 0 | 0 | $0 |
| Kenneth S Koblan | — | 8. Dezember 2010 A | — | 0 | 0 | $0 |
| Patricia L Allen | — | 8. Dezember 2010 A | 0 | 0 | 0 | $0 |
| James L Vincent | — | 18. Juni 2010 M | 0 | 0 | 0 | $0 |
| Vicki L Sato | — | 2. Juni 2010 A | — | 0 | 0 | $0 |
| Edward M Scolnick | — | 11. Juni 2009 A | — | 0 | 0 | $0 |
| John A Schmidt Jr | — | 9. Dezember 2008 A | — | 0 | 0 | $0 |
| Vincent J Miles | — | 7. Dezember 2005 A | — | 0 | 0 | $0 |
| Abingworth Management LTD | — | 3. Juni 2004 C | 18.745 | 0 | 0 | $0 |
Insider aus SEC-Einreichungen Form 3/4/5; Netto = nur P/S aus offenen Märkten
Aktivisten & 5%+-Eigentümer 2 Beteiligungen
Investoren mit SEC Schedule 13D — wirtschaftliches Eigentum über 5% mit der Absicht, Einfluss auf den Emittenten zu nehmen (aktivistische Beteiligungen, Board-Kampagnen, M&A). Jede Zeile zeigt den zuletzt bekannten Stand der Position dieses Melders.
| Anmelder | Eingereicht | Beteiligung | Status | Zweck | Einreichung |
|---|---|---|---|---|---|
| CHP II, L.P. IRSN, CHP II Management LLC IRSN, John K. Clarke, Brandon H. Hull, John J. Park, Lisa M. Skeete Tatum ×2 Einreichungen | 14. Februar 2007 | — | Erste Einreichung | — | SEC |
| CHP II, L.P IRSN, CHP II Management LLC IRSN, John K. Clarke, Brandon H. Hull, John J. Park, Lisa M. Skeete Tatum | 15. Februar 2006 | — | Erste Einreichung | — | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
ETF-Besitz Gehalten von 150 ETFs
Gewichtung spiegelt nur direkte Aktienbestände (N-PORT) wider; gehebelte oder derivatbasierte Fonds können zusätzliche Swap-Exposure halten, die hier nicht angezeigt wird.
| Fonds | Gewicht | Anteile | Stand | Quelle |
|---|---|---|---|---|
| PBE · Invesco Exchange-Traded Fund Trust | 3,25% | 53.807 SH | 8. August 2026 | Täglich |
| NUMG · Nushares ETF Trust | 3,23% | 36.910 NS | 30. April 2026 | N-PORT |
| MID · AMERICAN CENTURY ETF TRUST | 3,19% | 10.523 NS | 31. Mai 2026 | N-PORT |
| FMED · Fidelity Covington Trust | 2,79% | 3.791 NS | 31. Mai 2026 | N-PORT |
| IBB · iShares Trust | 2,21% | 976.319 SH | 8. August 2026 | Täglich |
| HTEC · EXCHANGE TRADED CONCEPTS TRUST | 2,01% | 3.468 NS | 30. April 2026 | N-PORT |
| BIB · ProShares Trust | 2,01% | 4.904 NS | 31. Mai 2026 | N-PORT |
| IBBQ · Invesco Exchange-Traded Fund Trust … | 1,99% | 7.268 SH | 8. August 2026 | Täglich |
| FDG · AMERICAN CENTURY ETF TRUST | 1,94% | 26.515 NS | 31. Mai 2026 | N-PORT |
| JMID · Janus Detroit Street Trust | 1,40% | 824 NS | 30. April 2026 | N-PORT |
| CAML · Professionally Managed Portfolios | 1,29% | 15.623 NS | 30. April 2026 | N-PORT |
| BBP · ETFis Series Trust I | 1,24% | 2.379 NS | 30. April 2026 | N-PORT |
| HRTS · Tema ETF Trust | 1,14% | 1.954 NS | 31. Mai 2026 | N-PORT |
| MEDI · Harbor ETF Trust | 1,08% | 966 NS | 30. April 2026 | N-PORT |
| LABU · Direxion Shares ETF Trust | 0,90% | 15.151 NS | 30. April 2026 | N-PORT |
| QQQE · Direxion Shares ETF Trust | 0,89% | 35.072 NS | 30. April 2026 | N-PORT |
| VOT · VANGUARD INDEX FUNDS | 0,88% | 1.022.888 SH | 8. August 2026 | Täglich |
| IWP · iShares Trust | 0,82% | 770.414 SH | 8. August 2026 | Täglich |
| JOET · Virtus ETF Trust II | 0,80% | 6.062 NS | 30. April 2026 | N-PORT |
| CGGR · Capital Group Growth ETF | 0,76% | 613.330 NS | 31. Mai 2026 | N-PORT |
| FHLC · FIDELITY COVINGTON TRUST | 0,66% | 60.901 NS | 30. April 2026 | N-PORT |
| VHT · VANGUARD WORLD FUND | 0,59% | 398.693 SH | 8. August 2026 | Täglich |
| FFLG · FIDELITY COVINGTON TRUST | 0,58% | 11.032 NS | 30. April 2026 | N-PORT |
| QNXT · iShares Trust | 0,54% | 699 SH | 8. August 2026 | Täglich |
| USMV · iShares Trust | 0,47% | 527.555 SH | 8. August 2026 | Täglich |
| IYH · iShares Trust | 0,47% | 79.894 SH | 8. August 2026 | Täglich |
| VXF · VANGUARD INDEX FUNDS | 0,45% | 1.532.109 SH | 8. August 2026 | Täglich |
| UPSD · ETF Series Solutions | 0,44% | 1.435 NS | 30. April 2026 | N-PORT |
| ILDR · First Trust Exchange-Traded Fund VI… | 0,43% | 4.118 NS | 31. Mai 2026 | N-PORT |
| QFLR · Innovator ETFs Trust | 0,39% | 6.430 NS | 30. April 2026 | N-PORT |
| VO · VANGUARD INDEX FUNDS | 0,39% | 2.893.468 SH | 8. August 2026 | Täglich |
| IMCG · iShares Trust | 0,38% | 72.243 SH | 8. August 2026 | Täglich |
| FXH · First Trust Exchange-Traded AlphaDE… | 0,38% | 10.723 NS | 30. April 2026 | N-PORT |
| ESMV · iShares Trust | 0,35% | 128 SH | 8. August 2026 | Täglich |
| SDG · iShares Trust | 0,33% | 2.658 SH | 8. August 2026 | Täglich |
| SMIZ · Zacks Trust | 0,31% | 2.688 NS | 31. Mai 2026 | N-PORT |
| ESLG · Strategy Shares | 0,31% | 196 NS | 30. April 2026 | N-PORT |
| JDOC · J.P. Morgan Exchange-Traded Fund Tr… | 0,31% | 112 NS | 30. April 2026 | N-PORT |
| HEQQ · J.P. Morgan Exchange-Traded Fund Tr… | 0,30% | 305 NS | 30. April 2026 | N-PORT |
| AVIE · AMERICAN CENTURY ETF TRUST | 0,28% | 94 NS | 31. Mai 2026 | N-PORT |
| HQGO · Lattice Strategies Trust | 0,26% | 404 NS | 30. April 2026 | N-PORT |
| LRND · New York Life Investments ETF Trust | 0,24% | 2.252 NS | 30. April 2026 | N-PORT |
| ESUM · Strategy Shares | 0,23% | 1.141 NS | 30. April 2026 | N-PORT |
| FBCG · FIDELITY COVINGTON TRUST | 0,23% | 45.231 NS | 30. April 2026 | N-PORT |
| JMOM · J.P. Morgan Exchange-Traded Fund Tr… | 0,22% | 15.559 NS | 30. April 2026 | N-PORT |
| QCLR · Global X Funds | 0,21% | 27 NS | 30. April 2026 | N-PORT |
| QYLG · Global X Funds | 0,21% | 953 NS | 30. April 2026 | N-PORT |
| IWR · iShares Trust | 0,21% | 542.695 SH | 8. August 2026 | Täglich |
| QRMI · Global X Funds | 0,21% | 108 NS | 30. April 2026 | N-PORT |
| QYLD · Global X Funds | 0,20% | 54.832 NS | 30. April 2026 | N-PORT |